VTGN (Vistagen Therapeutics, Inc. Common Stock) Stock Analysis - SEC Filings

Vistagen Therapeutics, Inc. Common Stock (VTGN) is a publicly traded Healthcare sector company. As of May 21, 2026, VTGN trades at $0.63 with a market cap of $23.59M and a P/E ratio of -0.38. VTGN moved +1.22% today. Year to date, VTGN is -11.14%; over the trailing twelve months it is -75.67%. Its 52-week range spans $0.43 to $5.14. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces VTGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find VTGN SEC filings?

Rallies organizes VTGN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

VTGN Key Metrics

Key financial metrics for VTGN
MetricValue
Price$0.63
Market Cap$23.59M
P/E Ratio-0.38
EPS$-1.67
Dividend Yield0.00%
52-Week High$5.14
52-Week Low$0.43
Volume822
Avg Volume0
Revenue (TTM)$486.00K
Net Income$-51.42M
Gross Margin0.00%

Latest VTGN News

VTGN Analyst Consensus

1 analysts cover VTGN: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.

Common questions about VTGN

Where can I find VTGN SEC filings?
Rallies organizes VTGN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show VTGN 10-K and 10-Q filings?
Rallies organizes VTGN SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is VTGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VTGN. It does not provide personalized investment advice.
VTGN

VTGN